Vaccine Therapies in Malignant Glioma

Taemin Oh, Eli T. Sayegh, Shayan Fakurnejad, Daniel Oyon, Jonathan Balquiedra Lamano, Joseph David Di Domenico, Orin Bloch, Andrew T. Parsa

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Glioblastoma is a grade IV astrocytoma that is widely accepted in clinical neurosurgery as being an extremely lethal diagnosis. Long-term survival rates remain dismal, and even when tumors undergo gross resection with confirmation of total removal on neuroimaging, they invariably recur with even greater virulence. Standard therapeutic modalities as well as more contemporary treatments have largely resulted in disappointing improvements. However, the therapeutic potential of vaccine immunotherapy for malignant glioma should not be underestimated. In contrast to many of the available treatments, vaccine immunotherapy is unique because it offers the means of delivering treatment that is highly specific to both the patient and the tumor. Peptide, heat-shock proteins, and dendritic cell vaccines collectively encapsulate the majority of research efforts involving vaccine-based treatment modalities. In this review, important recent findings for these vaccine types are discussed in the context of ongoing clinical trials. Broad challenges to immunotherapy are also considered.

Original languageEnglish (US)
JournalCurrent neurology and neuroscience reports
Issue number1
StatePublished - Jan 2015


  • Glioblastoma
  • Glioma
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Vaccine Therapies in Malignant Glioma'. Together they form a unique fingerprint.

Cite this